GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (NAS:RADX) » Definitions » Treasury Stock

RADX (Radiopharm Theranostics) Treasury Stock : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2050. Start your Free Trial

What is Radiopharm Theranostics Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Radiopharm Theranostics's treasury stock for the quarter that ended in Dec. 2023 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.


Radiopharm Theranostics Treasury Stock Historical Data

The historical data trend for Radiopharm Theranostics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Treasury Stock Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24
Treasury Stock
- - -

Radiopharm Theranostics Quarterly Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Treasury Stock Get a 7-Day Free Trial - - - - -

Radiopharm Theranostics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.


Radiopharm Theranostics Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.

Radiopharm Theranostics Headlines

From GuruFocus

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 07-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-20-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-30-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-10-2022

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire 10-19-2022